11 Best Fast Money Stocks To Buy Now

7. Rapport Therapeutics, Inc. (NASDAQ:RAPP)

Upside Potential as of September 29, 2025: 84.23%

Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial for RAP-219 in refractory focal epilepsy.

Keeping in view the year-to-date returns posted by Rapport Therapeutics, Inc. (NASDAQ:RAPP), the company outperformed the market by an impressive 45%. What’s even more interesting about the company is its recent data, which is defined by a large market of 1.8 million patients in the U.S., with 40% of them continuing to be treatment resistant.

During the presentation at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, the leadership expressed enthusiasm about its RAP-219, which they view as a multibillion-dollar market opportunity. As stated by the CEO, Abraham Ceesay,

And that’s really defined by a novel MOA with RAP-219; two, efficacy that we think is really best-in-class from what we’ve seen from our proof-of-concept study, a drug that’s generally well tolerated and consistent with precision biology.

Rapport Therapeutics, Inc. (NASDAQ:RAPP), headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company that develops medicines for individuals living with central nervous system (CNS) disorders. Incorporated in 2022, the company is committed to developing therapies with enhanced efficacy.